Seguimiento farmacoterapéutico y uso racional de inhibidores de la bomba de protones en pacientes pediátricos hematológicos: una revisión sistemática
DOI:
https://doi.org/10.53591/ydkj1580Palabras clave:
seguimiento farmacoterapéutico; inhibidores de la bomba de protones; uso racional de medicamentos; hematología pediátrica; atención farmacéutica.Resumen
El uso de inhibidores de la bomba de protones (IBP) es frecuente en la población pediátrica y se han descrito prácticas de prescripción potencialmente inapropiadas, especialmente en pacientes hospitalizados. En hematología pediátrica, la polifarmacia y la complejidad terapéutica hacen necesario evaluar periódicamente la necesidad, efectividad y seguridad de estos medicamentos. El objetivo de esta revisión sistemática fue analizar la evidencia publicada entre 2020 y 2025 sobre el seguimiento farmacoterapéutico y el uso racional de IBP en población pediátrica, con énfasis en su aplicabilidad a pacientes hematológicos. Se realizó una búsqueda y reconstrucción bibliográfica dirigida en PubMed/MEDLINE, Sco-pus, Web of Science, SciELO y Cochrane Library, siguiendo PRISMA 2020. La versión preliminar del manuscrito reportaba 642 registros, de los cuales 32 publicaciones fueron finalmente sintetizadas; durante la presente revisión editorial se verificó y caracterizó individualmente ese conjunto de 32 publicaciones. La evidencia directamente específica de hematología pediátrica fue limitada, por lo que se incorporó evidencia pediátrica general como evidencia indirecta y se diferenció expresamente de los antecedentes locales. Los hallazgos muestran uso frecuente de IBP, prescripciones potencialmente innecesarias o prolongadas y señales de seguridad relacionadas con infecciones, microbiota y otros desenlaces.
Referencias
Alla, D. S. (2024). Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review. Global Pediatric Health, 1–13. Obtenido de https://journals.sagepub.com/doi/10.1177/2333794X241248967
Andrawes, M., Andrawes, W., Das, A., & Siau, K. (2025). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. Medicina, 61(9), 1569. https://doi.org/10.3390/medicina61091569
Arnoux, A., et al. (2022). Estudio retrospectivo de adecuación del uso de inhibidores de la bomba de protones en niños hospitalizados.
Berry, J., & Mansbach, J. (2023). Questionable safety of proton pump inhibitor use in children. JAMA Pediatrics, 177(10), 1010–1012. https://doi.org/10.1001/jamapediatrics.2023.2906
Bramer, W. M., Rethlefsen, M. L., Kleijnen, J., & Franco, O. H. (2018). Optimal database combinations for literature searches in systematic reviews: A prospective exploratory study. Systematic Reviews, 6(1), 245. Obtenido de https://link.springer.com/article/10.1186/s13643-017-0644-y
Closs, M., et al. (2023). Use of proton pump inhibitors in Scandinavian children and adolescents: An observational study. Frontiers in Pediatrics, 11, 1052978.
Cochrane. (2023). Pharmacological treatment of gastro-oesophageal reflux in children. Cochrane Database of Systematic Reviews.
De Bruyne, P., & Ito, S. (2020). The effects of proton pump inhibitors on the microbiome in young children. Acta Paediatrica, 109(8), 1531–1538. https://doi.org/10.1111/apa.15213
DeCS – Descriptores en Ciencias de la Salud, D. –D.–D. (2025). Biblioteca Virtual en Salud (BVS). Obtenido de Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud (BIREME/OPS/OMS).: https://decs.bvsalud.org
Dekkers, O. M., Vandenbroucke, J. P., & Cevallos, M. (2023). Cochrane Handbook for Systematic Reviews of Interventions. Obtenido de Cochrane Handbook for Systematic Reviews of Interventions: https://www.cochrane.org/handbook
Dipasquale, V., et al. (2022). A narrative review on efficacy and safety of proton pump inhibitors in children. Frontiers in Pharmacology, 13, 839972. https://doi.org/10.3389/fphar.2022.839972
Dipasquale, V., et al. (2022). Spontaneous reporting of adverse reactions to proton pump inhibitors in children. Registro de farmacovigilancia pediátrica.
Dziechciarz, P., et al. (2020). Lactobacillus rhamnosus GG as adjunctive therapy during omeprazole treatment in children with GERD. Pediatric Gastroenterology, Hepatology & Nutrition, 23(3), 251–258. https://doi.org/10.5223/pghn.2020.23.3.251
Fernández-González, S. M., Moreno-Álvarez, A., & Solar-Boga, A. (2024). Proton Pump Inhibitors in Pediatric Gastroesophageal Reflux Disease: A Systematic Review of Randomized Controlled Trials. Children, 11(3), 296. Obtenido de https://doi.org/10.3390/children11030296
Fossmark, R., & Olaisen, M. (2024). Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors—A Review of Findings from Experimental Trials. Microorganisms, 12(6), 1110. doi:https://doi.org/10.3390/microorganisms12061110
Freedberg, D., Kim, L., & YX, Y. (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology., 152(4), 706-715. Obtenido de 10.1053/j.gastro.2017.01.031. PMID: 28257716.
Gudnadottir, U., et al. (2025). Prenatal and early childhood exposure to proton pump inhibitors and antibiotics and the risk of childhood cancer: A nationwide population-based cohort study. Drug Safety, 48(4), 375–388. https://doi.org/10.1007/s40264-024-01500-x
Jha, S., et al. (2024). Are PPI unsafe for pediatric use? Global Pediatric Health, 11. https://doi.org/10.1177/2333794X241307187
Johansson, S., Wettermark, B., Andersson Sundell, K., & Wallach-Kildemoes, H. (2024). Trends in proton pump inhibitor use in Sweden by sex and age: A drug utilisation study. Drug Safety, 47(10), 1065–1078. https://doi.org/10.1007/s40264-024-01502-9
Kyler, K. E., et al. (2024). Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children. Clinical and Translational Science, 17(4), e13782.
Lassalle, M., Zureik, M., & Dray-Spira, R. (2023). Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children. JAMA Pediatrics, 177(10), 1028–1038. doi:https://doi.org/10.1001/jamapediatrics.2023.2900
Lassalle, M., Zureik, M., & Dray-Spira, R. (2023). Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatrics, 177(10), 1028–1038. https://doi.org/10.1001/jamapediatrics.2023.2900
Lemmens, A.-S., Huysentruyt, K., & Vandenplas, Y. (2025). Why think twice before prescribing proton pump inhibitors. European Journal of Pediatrics, 184(3), 227. https://doi.org/10.1007/s00431-025-06058-z
Li, Y., et al. (2020). Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children. Annals of Translational Medicine, 8(23), 1548. https://doi.org/10.21037/atm-20-2284
Luu, L. D. W., et al. (2022). Changes to the upper gastrointestinal microbiotas of children with reflux oesophagitis and oesophageal metaplasia. Microbial Genomics, 8(9), mgen000870. https://doi.org/10.1099/mgen.0.000870
Marquez, C., Thompson, R., Feinstein, J. A., King, K., & Kempe, A. (2022). dentifying opportunities for pediatric medication therapy management in children with medical complexity. Journal of the American Pharmacists Association, 62(5), 1587–1595.e3. Obtenido de https://doi.org/10.1016/j.japh.2022.04.005
Maza Larrea, J. A., Moreno Zamudio, D., Gutiérrez Villegas, I., Peredo Gómez, K. M., & Fernández Rosas, S. (2023). Clinical impact of pharmacotherapeutic follow-up and pharmacist interventions in a reference hospital in Mexico City. Pharmacy Education, 23(1), 376–382. Obtenido de https://doi.org/10.46542/pe.2023.231.376382
Naina Mohamed, P. M. (2023). Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam medical journal, 59(2), 115–127. Obtenido de https://doi.org/10.4068/cmj.2023.59.2.115
National Library of Medicine, N. N. (2025). Medical Subject Headings (MeSH Browser). Obtenido de U.S. National Library of Medicine.: U.S. National Library of Medicine.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Mayo-Wilso. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. Obtenido de https://doi.org/10.1136/bmj.n71
Robinson, D. S., & Ruffner, M. A. (2022). Proton pump inhibitors in allergy: Benefits and risks. Journal of Allergy and Clinical Immunology: In Practice, 10(12), 3117–3123. https://doi.org/10.1016/j.jaip.2022.09.022
Rossi, A., Perrella, L., Scotti, S., Olmastroni, E., Galimberti, F., Ardoino, I. Casula, M. (2024). Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. Journal of Clinical Medicine, 13(20), 6283. doi:https://doi.org/10.3390/jcm13206283
Santos, J., Moura, R., & Azevedo, E. (2022). Seguimiento farmacoterapéutico y factores predictivos de problemas relacionados con el uso de medicamentos en cuidados intensivos pediátricos. Journal of Hospital Pharmacy and Health Services, 13(1), 722. doi:https://doi.org/10.30968/rbfhss.2022.131.0722
Schulthess-Lisibach, A. E., Lüthold, R. V., Tombez, C., Weir, K. R., Zangger, M., Chan, S., . . . Barbier, M. (2025). DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care. BMJ open. Obtenido de https://doi.org/10.1136/bmjopen-2024-094495
Solano, M., Jeannin, M., Anxionnat, R., Vardanega, R. A., Amsallem, D., Limat, S., & Clairet, n.-L. (2022). Impact of pharmacist medication review for paediatric patients: an observational study. International Journal of Pharmacy Practice, 420–426. doi:https://doi.org/10.1093/ijpp/riac037
Tan, Y., et al. (2023). A review of histamine-2 receptor antagonist and proton pump inhibitor therapy for GERD in neonates and infants. Paediatric Drugs, 25(5), 557–576. https://doi.org/10.1007/s40272-023-00580-z
Tasci, E., & Tasci, S. (2023). Estudio pediátrico de parámetros de repolarización ventricular antes y después de IBP. Cardiology in the Young, 33(4), 520–524. https://doi.org/10.1017/S104795112200138X
Tian, L., et al. (2023). Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1217306
Tian, L., Huang, C., Fu, W., Gao, L., Mi, N., Bai, M., . . . Meng, W. (2023). Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Frontiers in Pharmacology. Obtenido de https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1217306/full
Tisseyre, M., et al. (2025). Prenatal proton pump inhibitor exposure and serious infections in offspring during the first year of life: A nationwide cohort study. Drug Safety, 48(3), 265–277. https://doi.org/10.1007/s40264-024-01496-4
van Gestel, L. C., Adriaanse, M. A., Kanis, S. L., Mensink-Bout, S. M., Schoones, J. W., Numans, M. E., & Kiefte-de Jong, J. C. (2024). Determinants of and interventions for Proton Pump Inhibitor prescription behavior: A systematic scoping review. BMC Primary Care, 25, 208. Obtenido de https://link.springer.com/article/10.1186/s12875-024-02459-5
Vera Romero, E. K. (2018). Programa de seguimiento farmacoterapéutico en los pacientes del servicio de hematología del Hospital del Niño “Dr. Francisco de Icaza Bustamante” [Tesis de maestría, Universidad Regional Autónoma de los Andes].
Wang, Y., et al. (2020). Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children. JAMA Pediatrics, 174(6), 543–551. https://doi.org/10.1001/jamapediatrics.2020.0007
Wang, Y., et al. (2021). Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2020.5710
Wang, Y., et al. (2022). Association Between Proton Pump Inhibitor Use and Risk of Depression and Anxiety in Children. Clinical and Translational Science. https://doi.org/10.1111/cts.13225
Wang, Y., et al. (2022). Proton pump inhibitor use and risk of pneumonia in children: A self-controlled case series study.
Yadav, R., Bolia, R., & Bhat, N. K. (2021). Inappropriate prescribing of proton pump inhibitors in children: Insights from a survey. Indian Journal of Pediatrics, 88(10), 1055. https://doi.org/10.1007/s12098-021-03854-x
Yao, D. W. J., et al. (2021). Reassessing the use of proton pump inhibitors and histamine-2 antagonists in critically ill children: A systematic review and meta-analysis. Journal of Pediatrics, 228, 164–176.e7. https://doi.org/10.1016/j.jpeds.2020.09.011
Zhang, J., et al. (2023). Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota. BMC Microbiology. https://doi.org/10.1186/s12866-023-02895-w
Zhang, Y. J., et al. (2024). Longitudinal microbiome changes in children exposed to proton pump inhibitors. Clinical and Translational Gastroenterology, 15(9), e1. https://doi.org/10.14309/ctg.0000000000000703
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Edtih Vera Romero
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
